Melanoma Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

The indications under Section B are part of the Ontario PET Registry. Completion of a post scan form is required following the PET scan. Together the pre and post scan information will provide vital data to build evidence for use of PET for this indication. Accurately complete both the pre and post scan forms.

Referring Physician Name:							
Physician Phone: ()	ext.	Fax: ()	CPSO No:			
Patient Name:	SURNAME		GT NAME	MIDDLE			
OHIP Number:							
Telephone: ()	_	Postal Code:				
Date of birth:	////		Gender: M	F Other			

Relevant Clinical History:

Provide the most recent and relevant imaging report(s) and other relevant clinical history.

The following documents <u>must</u> be attached to this requisition:

Relevant Imaging Studies within the previous 3 months (i.e. CT, US, MR, Other)

Consult Note or Referral Letter; including relevant lab work/pathology, if relevant

Fax Instructions

Please fax the completed request form, along with the required supporting documentation, to the PET Centre of choice for appointment. A complete list of PET Centres and their contact information is available at <u>PET Centre Locations List | CCO Health</u>

Complete EITHER Section A or B (not both)

<u>Section A</u> – PET for the staging of patients with localized "high risk" melanoma, or for the evaluation of patients with isolated melanoma metastases, when surgery or other ablative therapies are being considered.

Indication (choose only one)
Staging of localized high risk melanoma
(e.g., lymph node metastases, satellitosis or intransit metastases, or deep head & neck melanoma)

Evaluation of isolated metastases

Attach the relevant diagnostic imaging reports (CT, US, MRI) & provide images to PET centre.

Physician Signature:

Date:

Melanoma Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

Complete EITHER Section A or B (not both)	Patient Name:					
* <u>Section B</u> – PET in Immunotherapy for Metastatic Melanoma						
Melanoma Demographics						
Type of Melanoma: 🗌 Cutaneous 🗌 Mucosal	Acral Lentiginous Uveal Unknown Primary					
BRAF Status: Wild Type Mutant Other molecular change (specify):						
Current line of Immunotherapy: Sirst Line Second Line Other (specify):						
Has the patient received prior adjuvant immunotherapy? Yes No						
Indication (choose only one)						
*Baseline Staging – PET for the baseline staging of patients prior to starting immunotherapy; or for patients who are receiving immunotherapy and have not previously had a baseline PET. (choose one)						
Baseline PET PRIOR to patients starting im	munotherapy					
Baseline PET for patients who are receiving	g immunotherapy, and have not previously had a Baseline PET					
*Response Assessment – PET for response assessment immunotherapy.	of patients with metastatic melanoma currently receiving					
Reason for PET: Early Response Assessment (choose one):	After 2 cycles After 3 cycles After 4 cycles					
End of Therapy Response Assessment (
Therapy Complete	Adverse Event Patient Decision					
	Response or Good Partial Response					
Immunotherapy Start Date: Date or Date or	f most recent Immunotherapy dose: YYYY-MM-DD					
Current Immunotherapy Regimen (select all that apply):	herapy 🗌 Anti PD1 & Anti CTLA-4 combination therapy					
Other (specify):						
Baseline PET scan available for comparison?						
YYYY-MM-DD Residual Lesion(s) on CT? Not Applicable (no CT available)						
No						
Yes (specify total number & locations): Number of lesi	ons: $\Box 1 \Box 2 \Box 3 \Box \ge 4$					
Location of les	sions: Lung Liver Bone Adrenal Brain					
	Other (specify):					
Does patient have clinical evidence of immune related adverse event(s)?						
Yes (select all that apply): Enterocolitis Fatig	ue 🗌 Hematological 🗌 Hepatitis 🗌 Hypophysitis					
🗌 Pancreatitis 🗌 Rash	Pneumonitis Peripheral neuropathy					
Sarcoidosis Thyro	Diditis Other (specify):					

Version Date: March 22, 2024

Page 2 of 3 *PET Centre Use Only: Registry Indication – PET Centre must submit pre- & post-scan forms to OH to be eligible for funding

Melanoma Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

<u>Complete EITHER Section A or B (not both)</u>

Г

Patient Name:_____

* <u>Section B (continued)</u>	 PET in Immunotherapy for Metastatic Melanoma 	

Select Management Plan – if PET were <u>NOT</u> available, what is your <u>Current Management Plan</u>						
Pre-PET Treatment Plan (select all that apply):						
	Start Immunotherapy (specify):	🗌 Anti PD1 Monotl	herapy			
		🗌 Anti PD1 & Anti	CTLA-4 combination therapy			
		🗌 Anti CTLA-4 Mor	notherapy			
		Other (specify):				
	Continue Immunotherapy					
	Discontinue Immunotherapy					
	Surgery					
	Targeted Therapy					
	Clinical Trial, (specify the protocol or SOC Name or Number):					
	Radiation					
	Chemotherapy, (specify both regimen &	k number of cycles):	a. Regimen			
			b. Number of Cycles:			
	Other, please describe					

Physician Signature:_____ Date: _____